Voucher Bargain: US FDA Lowers Redemption Fee; NDA And BLA Review Costs Decrease
Executive Summary
Additional fee will be less than traditional PDUFA application fee in FY 2019, meaning voucher redemptions will cost less than double a typical application review.
You may also be interested in...
A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.
US FDA's Streamlined Hiring Pilot Restarts After Delay
Recruiting for “Cures”-funded positions resulted in two hires, then got an HHS review; onboarding time should be reduced significantly, but finding the money to pay the higher salaries remains a challenge under the new process.
PDUFA Becomes US FDA's Billion Dollar Baby
Second consecutive year of record workload levels drive substantial increase in FDA's prescription drug user fee revenue target for fiscal year 2019.